Renal Safety of Ibandronate

Jackson, Graham

doi:10.1634/theoncologist.10-90001-14

Cited by 34 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanism of toxicity seems to be different for different types of BP and some are more nephrotoxic than others [97]. A retrospective study in 84 patients affected by MM and treated with BPs showed a better renal profile for Iban than for ZA [98], which was confirmed in other studies [99,100]. The kidneys are particularly sensitive to BPs, being responsible for 40% of the excretion of the BP via glomerular filtration and active tubular excretion [97].…”

Section: Renal Toxicitymentioning

confidence: 85%

The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future

Pozzi

Raje

2011

The Oncologist

View full text Add to dashboard Cite

show abstract

Section: Renal Toxicitymentioning

confidence: 85%

The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future

Pozzi

Raje

2011

The Oncologist

View full text Add to dashboard Cite

show abstract

“…bisphosphonates such as zoledronic acid. 24,[26][27][28][29] Thus, ibandronate may be a viable option in preventing bone loss especially in patients with pre-existing renal damage or those who develop renal insufficiency during the course of their allo-SCT. Furthermore, this trial evaluated doses used to treat post-menopausal osteoporosis and using higher doses in our patient population may need to be evaluated.…”

Section: Discussionmentioning

confidence: 99%

Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial

et al. 2016

View full text Add to dashboard Cite

The purpose of this study was to evaluate the effects of ibandronate on bone loss following allogeneic stem cell transplantation (allo-SCT). A single-centered, open-label prospective randomized-controlled study following allo-SCT. The treatment group received 3 mg of intravenous ibandronate quarterly starting within 45 days of allo-SCT. All patients received daily calcium and vitamin D supplements. We compared the changes in bone mineral density (BMD) in the lumbar spine, femoral neck and total hip at 6 and 12 months following allo-SCT between the control and treatment groups. We also assessed relationships between bone loss and cumulative glucocorticoid dose, cumulative tacrolimus dose and acute and chronic graft-versus-host disease (GVHD) by linear regression. In all, 78 patients were enrolled. The treatment group had significantly less BMD loss in the lumbar spine at 6 months (mean percent change 0.06±4.03 (treatment group) versus À 2.61 ± 4.2 (control group)) and 12 months (mean percent change 1.27 ± 5.29 (treatment group) versus À 1.81±4.49 (control group)) than the control group (P ¼ 0.03). Both groups lost more BMD in the femoral neck and total hip than in the lumbar spine at 6 and 12 months. The changes in BMD in the femoral neck and total hip did not differ significantly between groups. Both glucocorticoids and tacrolimus reduced BMD in the lumbar spine, but ibandronate prevented this loss. Ibandronate may reduce bone loss in the lumbar spine in patients who undergo allo-SCT, particularly those who have received high doses of glucocorticoids and/or tacrolimus.

show abstract

“…But in patients with CrCl < 30ml/min renal elimination is decreased, the concentration being approximately two times higher than in patients with normal renal function, so it is advisable to reduce the dose by half [31][32][33][34].…”

Section: Treatment Of Decreased Bone Mass In Chronic Kidney Disease Smentioning

confidence: 99%

Use of Bisphosphonates in Chronic Kidney Disease

Ozmen¹

2012

World J Nephrol Urol

View full text Add to dashboard Cite

The primary goal of treatment for post-menopausal osteoporosis (PMO) is reduction in fracture risk. Therefore, bisphosphonates (BF) are the most commonly used drugs for the treatment of osteoporosis. Because of their urinary elimination, bisphosphonates must be carefully administered in chronic kidney disease (CKD) patients. Renal toxicity seems different among these compounds, and it is basically due to their protein binding and the average lifespan of renal tissues. In practice, renal toxicity has been associated with infusion speed and excessive dosage. Treatment decisions are more difficult with stage 4 and especially stage 5 CKD who had fragility fractures. In spite of this, bisphosphonates can safely be used at stage to 1 -3 CKD stages, haemodialysis and after the kidney transplant. When bisphosphonates are given stage 4 CKD patients it seems reasonable to reduce the dose to 50%. There are few data on the efficacy (reduction in fracture risk) or safety of any BF in patients with stage 5 CKD.

show abstract

Renal Safety of Ibandronate

Cited by 34 publications

References 14 publications

The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future

The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future

Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial

Use of Bisphosphonates in Chronic Kidney Disease

Contact Info

Product

Resources

About